Greater Asia News
Curiox Biosystems Inc., Announces Initial Public Offering (IPO)
Curiox Biosystems Inc., a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis, announced today the pricing of its initial public offering of 1,400,000 shares of its common stock at a price to the public of 13,000 won per share.
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).
Japanese and Chinese Healthcare Companies Dominate in Asian Capital Market
A review of the top 25 Healthcare companies in Asia-Pacific
Vatech Announces Distribution Through Henry Schein to Help Oral Health Professionals Enhance Access to Cutting-Edge Imaging Solutions
Vatech, a global leader in the dental imaging market, has announced that its products will be distributed by Henry Schein, helping to expand the availability of its cutting-edge products for dental clinics in North America.
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, "Poseida") today announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam).
Sunbird Bio Merges with Glympse Bio to Accelerate Development of Proprietary Protein-Based Diagnostic Technologies
Sunbird Bio, a biotechnology company developing proprietary protein-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced that they have completed a merger with Glympse Bio to accelerate development of the companies’ protein-based diagnostic platforms.
Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug
Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE).
Dr. Reddy’s Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).
SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.
